Market Trends of Mice Model Industry
The Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period
The primary factor propelling the oncology segment's growth is the rising burden of cancer, coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development research. For instance, in February 2021, ExpreS2ion Biotech Holding and the University of Bologna entered into a research collaboration agreement that covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001 in proprietary state-of-the-art breast cancer mice models.
In addition, the increasing research using mice models for drug discovery for cancer is also anticipated to contribute to the market growth. For example, as per the article published by OncoImmunology in April 2022, the researchers utilized the Diversity Outbred (DO) and Collaborative Cross (CC) mouse models to investigate the outcomes of the immune checkpoint inhibitors (ICI) for a variety of malignancies. The study researchers purchased the DO mice models from the Jackson Laboratory and all CC mice from the Systems Genetics Core Facility at the University of North Carolina. Such adoption of mice models in cancer research is expected to contribute to segment growth.
Product launches by the key market players support the market growth over the forest period. For instance, in January 2023, Taconic Biosciences launched the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic's widely used HIS portfolio. huNOG-EXL EA significantly lengthens the study window during which a myeloid-lineage HIS mouse model can be used successfully.
Thus, the abovementioned factor is expected to boost the segment growth over the forecast period.
North America is Expected to Hold a Significant Growth in the Mice Model Market
North America is anticipated to witness growth over the forecast period due to increased healthcare expenditure, increased research and development, and a rising prevalence of infectious or non-communicable diseases. The market players in the country are involved in multiple activities, such as collaborations and agreements, which are anticipated to drive market growth over the forecast period.
For instance, in May 2021, the SDS Alliance launched a Mouse Model Project with the Jackson Laboratory. The project will create the mouse model (introduce SDS disease genes into mice using CRISPR and breed) for USD 150,000 and characterize the model (such as how SDS present in mice compared to human SDS or whether the mice get pancreatic problems or neutropenia) for another USD 150,000.
In addition, in November 2021, Tranquis Therapeutics, a private immuno-neurology company, declared positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting. The data illustrate the potential of TQS-168 for treating amyotrophic lateral sclerosis (ALS). TQS-168 showed increased median survival and decreased pro-inflammatory cytokines and inflammatory monocytes in a widely used SOD1-G93A transgenic mouse model and demonstrated a similar decrease in inflammatory monocytes in blood from ALS patients. Such advances in the region are anticipated to fuel market growth.
Therefore, owing to the abovementioned factors, North America is predicted to witness growth over the forecast period.
